enVVeno Medical Corporation (NASDAQ:NVNO – Get Rating) shares were up 2.5% during mid-day trading on Thursday . The company traded as high as $5.31 and last traded at $5.29. Approximately 26,346 shares were traded during mid-day trading, an increase of 54% from the average daily volume of 17,160 shares. The stock had previously closed at $5.16.
enVVeno Medical Stock Performance
The business has a fifty day moving average of $5.46 and a 200-day moving average of $5.87. The company has a market capitalization of $48.01 million, a P/E ratio of -1.97 and a beta of 1.27.
Hedge Funds Weigh In On enVVeno Medical
An institutional investor recently bought a new position in enVVeno Medical stock. Dimensional Fund Advisors LP acquired a new stake in shares of enVVeno Medical Corporation (NASDAQ:NVNO – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 21,489 shares of the company’s stock, valued at approximately $135,000. Dimensional Fund Advisors LP owned approximately 0.23% of enVVeno Medical at the end of the most recent quarter. 23.05% of the stock is currently owned by institutional investors and hedge funds.
enVVeno Medical Company Profile
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
- Get a free copy of the StockNews.com research report on enVVeno Medical (NVNO)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.